Safety analysis by treatment periods from EMERALD-1: A phase 3, randomized, placebo-controlled study of transarterial chemoembolization with durvalumab with/without bevacizumab in participants with embolization-eligible unresectable hepatocellular carcinoma Meeting Abstract
| Authors: | Kudo, M.; Chan, S. L.; Sangro, B.; Erinjeri, J. P.; Qin, S.; Ren, Z.; Arai, Y.; Breder, V. V.; Lin, S. M.; Peron, J. M.; Nguyen, T. Q.; Yan, L.; Chiu, C. F.; Santos, F. A.; Veluvolu, A.; Thungappa, S. C.; Morgan, C.; Parsons, K.; Xynos, I.; Lencioni, R. |
| Abstract Title: | Safety analysis by treatment periods from EMERALD-1: A phase 3, randomized, placebo-controlled study of transarterial chemoembolization with durvalumab with/without bevacizumab in participants with embolization-eligible unresectable hepatocellular carcinoma |
| Meeting Title: | 2024 ASCO Breakthrough: A Global Summit for Oncology Innovators |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 42 |
| Issue: | 23 Suppl. |
| Meeting Dates: | 2024 Aug 8-10 |
| Meeting Location: | Yokohama, Japan |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2024-08-10 |
| Start Page: | 65 |
| Language: | English |
| DOI: | 10.1200/JCO.2024.42.23_suppl.65 |
| PROVIDER: | EBSCOhost |
| PROVIDER: | cinahl plus with full text |
| DOI/URL: | |
| Notes: | Meeting abstract: 65 -- Also held virtually -- Source: CINAHL Plus with Full Text |
